How India's Patent Office Destroyed Gilead's Global Game Plan

The door is now open for India's pharmaceutical companies to make a generic version of the U.S. drugmaker's blockbuster treatment for hepatitis C—and sell it all over the world

The headquarters of Gilead Sciences in Foster City, Calif.

Photographer: Tripplaar Kristoffer/SIPA via AP Images

Gilead Sciences charges a lot for the hepatitis treatment Sovaldi, which sells for as much as $84,000 to U.S. patients. The innovative medication has become one of the world's best-selling drugs despite its price tag, fueling huge growth at Gilead. The company had revenue of $24.2 billion in 2014, according to analysts' estimates, more than double its sales in 2013. Earnings for last year are projected to reached $12.8 billion, more than four times higher.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.